BRD4 and metabolic dysfunction-associated steatotic liver disease: To assess the effects of BRD4 on lipid accumulation in hepatocytes during MASLD progression, AML12 or primary mouse hepatocytes were exposed to 500 μM PA to induce an in vitro model of hepatocellular lipotoxicity [25–27].